摘要
目的:探讨艾塞那肽与胰岛素治疗新诊断2型糖尿病(T2DM)合并肥胖患者的减重及降糖效果差异。方法:选择2016年3月~2017年2月本院新诊断的T2DM合并肥胖患者98例,随机分为对照组、艾塞那肽组,各49例。对照组患者接受口服降糖药联合胰岛素治疗,艾塞那肽组患者接受艾塞那肽联合口服降糖药治疗。对比两组患者治疗前、治疗3个月后体重指数(BMI)、血糖水平及炎症因子含量的差异。结果:治疗前,两组患者的BMI、外周血血糖、血清炎症因子含量的差异无统计学意义(P>0.05)。治疗3个月后,艾塞那肽组患者的BMI低于对照组患者(P<0.05);艾塞那肽组外周血血糖指标空腹血糖(FBG)、餐后2h血糖(2hBG)水平低于对照组(P<0.05);艾塞那肽组血清中炎症因子白介素-6(IL-6)、血管细胞黏附分子-1(VCAM-1)、单核细胞趋化蛋白-1(MCP-1)、肿瘤坏死因子α(TNF-α)含量低于对照组患者(P<0.05)。结论:新诊断T2DM合并肥胖患者接受艾塞那肽联合口服降糖药治疗,可更为有效降低患者体重并优化血糖水平、减轻全身微炎症状态。
Objective:To explore the different weight-loss and hypoglycemic effects of exenatide and insulin treatment of patients with newly diagnosed T2 DM combined with obesity.Methods:98 cases of patients with newly diagnosed T2 DM complicated by obesity in this hospital between March 2016 and February 2017 were randomly divided into the control group(n=49)and the exenatide group(n=49).Control group received oral hypoglycemic drugs combined with insulin therapy,and exenatide group received exenatide combined with oral hypoglycemic drug therapy.The differences in BMI levels,blood glucose levels and inflammatory factor contents were compared between the two groups of patients before and after treatment.Results:Before treatment,there was no statistically significant difference in BMI levels,blood glucose index levels in peripheral blood and inflammatory factor contents in serum between the two groups.After 3 months of treatment,the BMI level in exenatide group was lower than that in control group;blood glucose indexes FBG and 2 hBG levels in peripheral blood of exenatide group were lower than those of control group;inflammatory factors IL-6,VCAM-1,MCP-1 and TNF-αcontents in serum of exenatide group were lower than those of control group.Conclusion:Exenatide combined with oral hypoglycemic drug therapy can more effectively reduce the body weight,optimize the blood glucose level and relieve the systemic micro-inflammatory state in patients with newly diagnosed T2 DM combined with obesity.
出处
《海南医学院学报》
CAS
2018年第4期488-491,共4页
Journal of Hainan Medical University
基金
白求恩基金管理委员会基层医院内分泌医生定点培养项目(20140901)~~
